The National Institutes of Health recently launched the Alzheimer’s Big Data portal, a website that represents part of the Accelerating Medicines Partnership (AMP) featuring a collaborating between the NIH, the U.S. Food and Drug Administration and scientists from a variety of disciplines. The AMP-AD Knowledge Portal is intended to facilitate the sharing of large datasets that accelerate the development of drug discovery as it relates to Alzheimers Disease (AD). Developed by Sage Bionetworks, a non-profit organization that promotes “open science,” the site will not only serve as a data repository for data about Alzheimers but also accelerate data sharing that leads to predictive modeling of the disease as well as the identification and elaboration of molecular pathways associated with the progression of Alzheimers Disease. Sage Bionetworks will work with academic teams and research collaborators to analyze data from over 2,000 post-mortem Alzheimer patient brain samples in addition to fostering sharing about methodologies for cutting-edge, big data analytics as it applies to Alzheimers, more generally. The portal promises to transform Alzheimers treatment by unlocking the power of Big Data analytics to facilitate disruptive and novel approaches to drug discovery and therapeutic approaches toward Alzheimers.